Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of ...

Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of efficacy over placebo. Martin Holst Lange, executive vice president for ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark shortly after it ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings, phone calls, and ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

Novo Nordisk's GLP-1 receptor agonist semaglutide ... better than placebo at resolving MASH and improving liver fibrosis, meeting its primary efficacy objectives. Analysts have suggested that ...